🇺🇸 FDA
Pipeline program

ET1402L1-ARTEMIS™ T cells -IV

XJTU1AF2017LSL-C002

Phase 1 mab completed

Quick answer

ET1402L1-ARTEMIS™ T cells -IV for Hepatocellular Carcinoma is a Phase 1 program (mab) at AEON Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
AEON Biopharma
Indication
Hepatocellular Carcinoma
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials